Bioarctics Alzheimerresultat hyllas i internationella medier

"Historiskt", "en möjlig seger", "fantastisk vändning". Nyheten om att svenskutvecklade lecanemab i en fas III-studie ser ut att kunna bromsa tidig Alzheimers har fått stor uppmärksamhet i internationell media.

Laskerpriset går till forskare bakom realtidsövervakning av covid-19

Hela världen har kunnat följa smittspridningen av covid-19 i realtid. Nu får Lauren Gardner Årets Laskerpris för att ha gjort det möjligt.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.

Business Sweden’s new team is rolling out the blue-yellow carpet

According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta Stenson.

”Vi vill vara ett startup-företag med akademisk anda”

Långvarig smärta och alzheimer. Två sjukdomar som plågar många människor världen över och som verkar omöjliga att rå på. Men Huddingeföretaget Alzecure arbetar med att utveckla läkemedel mot båda tillstånden.

Novo Nordisks studie: Insulin en gång i veckan gav bättre effekt

Data från det danska läkemedelsbolagets Onwards-studie tyder på att insulin som ges en gång per vecka har större effekt än insulin som ges varje dag.

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.

Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”

For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.

Pharmnovo startar kliniska studier – och förstärker sitt team

I augusti startade läkemedelsbolaget Pharmnovo kliniska studier av bolagets läkemedelskandidat mot nervsmärta. Nu meddelar bolaget att de stärker upp organisationen med Tommy Nilsson som CFO och Jarkko Kalliomäki som ledare för det kliniska arbetet.

Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"

The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.

Genes from Neanderthals can affect the correct drug dosage

A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for the drug doses they should take.

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.

Xintelas styrelse rekommenderar: Nobba uppköpsbudet

Biomedicinbolaget Xintelas styrelse rekommenderar aktieägarna att säga nej till ett uppköpserbjudande från Flerie Invest. "Detta baseras främst på den framtida potentialen och att Flerie Invests ambition inte varit att förvärva samtliga aktier", skriver styrelsen i ett pressmeddelande.

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

Sverige i jumboligan – få sjukhussängar per person

I en undersökning över hur många sjukhussängar OECD-länderna har per person hamnar Sverige hamnar på plats fem, från botten.

FHM: Smittspridningen av covid-19 väntas öka i höst

Semestern är slut, och skolor och arbetsplatser fylls med människor igen. Idag kommer Folkhälsomyndigheten med nya scenarier inför hösten – smittspridningen av covid-19 väntas öka, med en topp i slutet av september.

Studie med läkemedel mot nervsmärta startar

Lundaföretaget Pharmnovo påbörjar nu kliniska studier med sin läkemedelskandidat mot neuropatisk smärta.

Sweden is heavily criticised for not ordering Covid vaccine

Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.

Newly discovered gene variant linked to protection against abdominal obesity

American researchers believe they have identified a rare gene mutation that protects against abdominal obesity and metabolic syndrome. The ambition is that the discovery will lead to new treatments that can help reduce the risk of type 2 diabetes and coronary artery disease.

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s

EQT lägger bud på Karo Pharma